LYMPHOMA, T-CELL
Clinical trials for LYMPHOMA, T-CELL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T-CELL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug may keep T-Cell lymphoma at bay after transplant
Disease control Recruiting nowThis phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 24, 2026 08:47 UTC
-
New hope for tough lymphoma: targeted drug soquelitinib faces standard care in phase 3 trial
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard treatments for people with certain types of T-cell lymphoma that have come back or stopped responding to therapy. About 150 adults will be randomly assigned to receive either soquelitinib or a standard single-agent …
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New hope for tough lymphomas: experimental drug STP938 enters human trials
Disease control Recruiting nowThis study is for adults with B-cell or T-cell lymphoma that has returned or stopped responding to at least two prior treatments. The drug, STP938, blocks a protein cancer cells need to grow. The trial has two parts: first, finding a safe dose (Phase 1), then testing how well it …
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE1, PHASE2 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
Experimental CAR T-Cell therapy takes on tough lymphoma
Disease control Recruiting nowThis study tests an experimental treatment called MB-105 for people with a type of blood cancer called T-cell lymphoma that has come back or not responded to standard treatments. MB-105 is made from a patient's own immune cells, which are modified in a lab to better recognize and…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: March Biosciences Inc • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New hope for rare blood cancers: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have not responded to standard therapy. The goal is to see if the drug can shrink or control the cancer. About 48 adults will take the drug by mouth, and researchers…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC